Asset Dedication LLC’s Kyntra Bio KYNB Stock Holding History

Asset Dedication LLC’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-20	Closed	-$19K	–	705
2020 Q4	$19K	Buy	+20	New	+$21K	﹤0.01%	474

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Asset Dedication LLC's KYNB Position: Q1 2021 in Review

Asset Dedication LLC sold out of Kyntra Bio (KYNB) in Q1 2021, closing a stake of 20 shares — an estimated $19K sold.

Asset Dedication LLC first reported a position in KYNB in Q4 2020 and held it in 1 quarter. The position peaked at $19K in Q4 2020. 198 funds tracked by Wall St. Rank hold KYNB as of Q1 2021.

Asset Dedication LLC reported no remaining Kyntra Bio position as of Q1 2021 after selling out during the quarter.
Asset Dedication LLC sold 20 Kyntra Bio shares in Q1 2021, an estimated $19K.
Asset Dedication LLC first reported a position in Kyntra Bio in Q4 2020 and held it in 1 quarter.
Asset Dedication LLC's Kyntra Bio position peaked at $19K in Q4 2020.
198 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2021.

Based on Asset Dedication LLC's 13F filing for Q1 2021, filed 3 May 2021.